View ValuationNovacyt 将来の成長Future 基準チェック /16 Novacytは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.0%収益成長率13.0%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日10 Oct 2025今後の成長に関する最新情報お知らせ • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.お知らせ • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.お知らせ • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).お知らせ • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).すべての更新を表示Recent updatesお知らせ • May 26Novacyt S.A., Annual General Meeting, Jun 30, 2026Novacyt S.A., Annual General Meeting, Jun 30, 2026. Location: hotel hilton paris charles de gaulle aeroport, paris Franceお知らせ • May 21Novacyt S.A. Launches Yourgene Insight DPYD AssayNovacyt S.A. announced the launch of Yourgene Insight DPYD assay, an assay utilizing genetic Insights for safer chemotherapy treatments to align with updated testing guidelines. Yourgene Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients globally are treated with fluoropyrimidines (including 5-FU) each year; 10-20% of these patients suffer severe, and sometimes fatal side effects associated with DPD deficiency. Screening patients for DPYD variants allows treatments to be adjusted accordingly. Following updated guidelines from a joint consensus of organizations such as AMP (Association for Molecular Pathology) and ACMG (American College of Medical Genetics and Genomics), the 2019 original Yourgene DPYD test has been enhanced to enable the number of variants to be detected to increase from six to 19, including the 14 recommended by these updated guidelines. The product has been launched for Research Use Only (RUO) initially with In Vitro Diagnostic Regulation (IVDR) and other regulatory territory approvals to follow in due course. Many countries have already implemented DPYD genotyping ahead of prescribing chemotherapy treatment and there is a mixed model of private pay and reimbursement. The Yourgene Insight DPYD test has the same workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day, ensuring there is no delay in patients starting their chemotherapy treatment. The Company has continued to invest in research and development to expand its product portfolio, and it is encouraging to see this investment translating into commercially launched products and tangible pipeline progress.お知らせ • May 10Novacyt S.A. Announces Departure of Chief Scientific Officer and Board Member Dr Joanne Mason, Effective 7 May 2026Novacyt S.A. announces that Dr Joanne Mason is stepping down as Chief Scientific Officer and a member of the Board of Novacyt, with immediate effect, to enable her to pursue other business opportunities.お知らせ • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.お知らせ • Apr 08Novacyt S.A. to Report Fiscal Year 2025 Results on Apr 30, 2026Novacyt S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026お知らせ • Mar 03Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million.Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,961,840 Price\Range: €0.4 Transaction Features: Rights Offeringお知らせ • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.お知らせ • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).お知らせ • Sep 18Novacyt S.A. to Report First Half, 2025 Results on Sep 30, 2025Novacyt S.A. announced that they will report first half, 2025 results on Sep 30, 2025お知らせ • Jul 16Novacyt S.A. Announces the Launch of LightBench® DiscoverNovacyt S.A. announced the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. The concept for the LightBench® Discover was developed following a close collaboration with PacBio®, where Yourgene Health became a PacBio® Compatible Partner for the original LightBench®? in November 2023. As part of product development for LightBench® Discover, Novacyt deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real world samples to assess the instruments' performance. LightBench® Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench®? Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench®) for large fragment analytics up to 150 kilobases, along with size selection and quantification functions, making it ideal for research applications utilising long read sequencing on the PacBio Revio®? or Vegatm systems. The Company has released the Technical Note showcasing data from its collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website <URL> and on the PacBio®? Compatible Partners webpage.お知らせ • May 15Novacyt S.A., Annual General Meeting, Jun 19, 2025Novacyt S.A., Annual General Meeting, Jun 19, 2025. Location: hotel hilton paris charles de gaulle aeroport, velizy villacoublay Franceお知らせ • Apr 22Novacyt S.A. to Report Fiscal Year 2024 Results on Apr 30, 2025Novacyt S.A. announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 30, 2025お知らせ • Feb 22Novacyt S.A. Announces IVDR Accreditation for Yourgene®? QST*R Base AssayNovacyt S.A. announced that it has receivedaccreditation under the new EU requirements of theIn VitroDiagnostic Regulation ("IVDR") for theYourgene® QSTRBaseassay.TheYourgene® QSTRBaseis a Class Cin vitromedical device under IVDR and is intended for use by healthcare professionals within a molecular laboratory environment. Yourgene® QSTR Base is a highly multiplexed, single tube assay containing 22 markers for rapid diagnosis of the common autosomal and sex chromosome aneuploidies during pregnancy. For those women identified as being at high risk of carrying a fetus with one of these conditions, chorionic villus sampling (10-12 weeks) or amniocentesis (14-18 weeks) is offered and QSTR Base would then be used by the laboratory. Autosomal markers are used to detect the three most common viable autosomal trisomies: trisomy 21 (Down's syndrome), trisomy 18 (Edwards' syndrome) and trisomy 13 (Patau's syndrome). The chosen markers are highly informative with results obtained in >99% of samples. IVDR ensures that the Yourgene® QSTR Base assay, which is manufactured for sale in the EU, is assessed against stringent quality, safety and performance requirements. Manufacturers must provide considerable evidence of scientific validity, as well as data demonstrating analytical and clinical performance of the tests. The Yourgene® QSTR Base assay was assessed by British Standards Institution (BSI), an independent conformity assessment body, and was shown to conform to the new regulations.お知らせ • Oct 08Novacyt S.A. Closure of IT-IS International LimitedNovacyt S.A. announced the closure of its IT-IS International Limited ("IT-IS") subsidiary, effective immediately. IT-IS, a Stokesley-based manufacturer of rapid-PCR instruments, was acquired by Novacyt in 2020 to support the Group's response to COVID-19, where it facilitated the full delivery of the Group's contracts during the period. The PCR instrumentation market has since become saturated, with IT-IS subsequently experiencing several consecutive loss-making years. IT-IS contributed £0.3m to the Group's total revenue in H1 2024 (H1 2023: £0.6million). The Intellectual Property ("IP") that exists within IT-IS will be retained to allow Novacyt to continue an ongoing IP infringement dispute with Roche Diagnostics GmbH. The dispute, instigated by IT-IS, dates back over five years and is currently progressing through the German courts. The Group will provide further updates on the dispute when appropriate.お知らせ • Sep 26Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024Novacyt S.A. announces the appointment of Dr. John Brown CBE as Chairman effective from 1 October 2024. Dr. Brown was appointed Non-executive Director of Novacyt in September 2023 following the acquisition of Yourgene Health and will succeedJames Wakefield, who is retiring from the Board having been Chairman since before the company joined AIM in 2017. Dr. Brown has over 38 years industry experience, which includes significant capital markets and board experience in the healthcare and life sciences sector. He is currently Chairman of Laverock Therapeutics Ltd. and Calcivis Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd. and CXR Biosciences Ltd. and Senior Non-Executive Director of Quantum Pharma plc. Dr. Brown was appointed to the Board of Yourgene Health in July 2019 as a Non-executive Director and became Chairman in April 2022.お知らせ • Sep 12Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024Novacyt S.A. announced that they will report first half, 2024 results on Sep 26, 2024お知らせ • May 22Novacyt S.A., Annual General Meeting, Jun 26, 2024Novacyt S.A., Annual General Meeting, Jun 26, 2024. Location: velizy villacoublay Franceお知らせ • May 21Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024Novacyt S.A. announced that they will report fiscal year 2023 results on May 30, 2024お知らせ • May 01Novacyt S.A. Notes DHSC Application for Summary Judgment DismissedNovacyt S.A. noted the judgment by Mrs. Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs. Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment. The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.お知らせ • Apr 12+ 1 more updateNovacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024Novacyt S.A. announced that James McCarthy will step down from the Board, effective from 1 May 2024. Dr. Andrew Health, Non-Executive Director will retire from the Board of Directors effective 1 May 2024.お知らせ • Sep 13Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023Novacyt S.A. announced that they will report Q2, 2023 results on Sep 28, 2023お知らせ • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).お知らせ • May 10Novacyt S.A., Annual General Meeting, Jun 15, 2023Novacyt S.A., Annual General Meeting, Jun 15, 2023, at 14:00 Central European Standard Time.業績と収益の成長予測OTCPK:NVYT.F - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202726N/A-5N/A112/31/202623N/A-7N/A112/31/202520N/A-12N/A16/30/202519-28-8-6N/A3/31/202520-34-10-8N/A12/31/202420-39-12-10N/A6/30/202417-33-30-29N/A3/31/202414-29-28-27N/A12/31/202311-24-26-25N/A9/30/20239-25-22-22N/A6/30/20238-25-18-18N/A3/31/202314-24-16-16N/A12/31/202221-22-14-14N/A9/30/202239-1156N/A6/30/20225712426N/A3/31/202275-21821N/A12/31/202193-61216N/A9/30/2021179403942N/A6/30/2021266856669N/A3/31/20212721098486N/A12/31/2020277132102103N/A9/30/2020173836162N/A6/30/202068332121N/A3/31/202040151010N/A12/31/201911-3-1-1N/A9/30/201912-3-10N/A6/30/201913-2-10N/A3/31/201912-2N/A-1N/A12/31/201812-2N/A-1N/A6/30/201811-3N/A-4N/A3/31/201811-3N/A-4N/A12/31/201711-3N/A-4N/A9/30/201712-4N/A-3N/A6/30/201712-3N/A-3N/A3/31/201710-4N/A-2N/A12/31/20169-5N/A-2N/A9/30/20169-9N/A-3N/A6/30/20168-13N/A-3N/A3/31/20167-12N/A-4N/A12/31/20157-10N/A-4N/A9/30/20156-7N/A-4N/A6/30/20156-4N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NVYT.Fの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NVYT.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NVYT.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NVYT.Fの収益 ( 13% ) US市場 ( 11.2% ) よりも速いペースで成長すると予測されています。高い収益成長: NVYT.Fの収益 ( 13% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NVYT.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/01 18:09終値2026/01/02 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Novacyt S.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Christophe-Raphael GanetODDO BHF Corporate & MarketsChristian GlennieStifel, Equities Research
お知らせ • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.
お知らせ • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.
お知らせ • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).
お知らせ • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).
お知らせ • May 26Novacyt S.A., Annual General Meeting, Jun 30, 2026Novacyt S.A., Annual General Meeting, Jun 30, 2026. Location: hotel hilton paris charles de gaulle aeroport, paris France
お知らせ • May 21Novacyt S.A. Launches Yourgene Insight DPYD AssayNovacyt S.A. announced the launch of Yourgene Insight DPYD assay, an assay utilizing genetic Insights for safer chemotherapy treatments to align with updated testing guidelines. Yourgene Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients globally are treated with fluoropyrimidines (including 5-FU) each year; 10-20% of these patients suffer severe, and sometimes fatal side effects associated with DPD deficiency. Screening patients for DPYD variants allows treatments to be adjusted accordingly. Following updated guidelines from a joint consensus of organizations such as AMP (Association for Molecular Pathology) and ACMG (American College of Medical Genetics and Genomics), the 2019 original Yourgene DPYD test has been enhanced to enable the number of variants to be detected to increase from six to 19, including the 14 recommended by these updated guidelines. The product has been launched for Research Use Only (RUO) initially with In Vitro Diagnostic Regulation (IVDR) and other regulatory territory approvals to follow in due course. Many countries have already implemented DPYD genotyping ahead of prescribing chemotherapy treatment and there is a mixed model of private pay and reimbursement. The Yourgene Insight DPYD test has the same workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day, ensuring there is no delay in patients starting their chemotherapy treatment. The Company has continued to invest in research and development to expand its product portfolio, and it is encouraging to see this investment translating into commercially launched products and tangible pipeline progress.
お知らせ • May 10Novacyt S.A. Announces Departure of Chief Scientific Officer and Board Member Dr Joanne Mason, Effective 7 May 2026Novacyt S.A. announces that Dr Joanne Mason is stepping down as Chief Scientific Officer and a member of the Board of Novacyt, with immediate effect, to enable her to pursue other business opportunities.
お知らせ • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.
お知らせ • Apr 08Novacyt S.A. to Report Fiscal Year 2025 Results on Apr 30, 2026Novacyt S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026
お知らせ • Mar 03Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million.Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,961,840 Price\Range: €0.4 Transaction Features: Rights Offering
お知らせ • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.
お知らせ • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).
お知らせ • Sep 18Novacyt S.A. to Report First Half, 2025 Results on Sep 30, 2025Novacyt S.A. announced that they will report first half, 2025 results on Sep 30, 2025
お知らせ • Jul 16Novacyt S.A. Announces the Launch of LightBench® DiscoverNovacyt S.A. announced the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. The concept for the LightBench® Discover was developed following a close collaboration with PacBio®, where Yourgene Health became a PacBio® Compatible Partner for the original LightBench®? in November 2023. As part of product development for LightBench® Discover, Novacyt deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real world samples to assess the instruments' performance. LightBench® Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench®? Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench®) for large fragment analytics up to 150 kilobases, along with size selection and quantification functions, making it ideal for research applications utilising long read sequencing on the PacBio Revio®? or Vegatm systems. The Company has released the Technical Note showcasing data from its collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website <URL> and on the PacBio®? Compatible Partners webpage.
お知らせ • May 15Novacyt S.A., Annual General Meeting, Jun 19, 2025Novacyt S.A., Annual General Meeting, Jun 19, 2025. Location: hotel hilton paris charles de gaulle aeroport, velizy villacoublay France
お知らせ • Apr 22Novacyt S.A. to Report Fiscal Year 2024 Results on Apr 30, 2025Novacyt S.A. announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 30, 2025
お知らせ • Feb 22Novacyt S.A. Announces IVDR Accreditation for Yourgene®? QST*R Base AssayNovacyt S.A. announced that it has receivedaccreditation under the new EU requirements of theIn VitroDiagnostic Regulation ("IVDR") for theYourgene® QSTRBaseassay.TheYourgene® QSTRBaseis a Class Cin vitromedical device under IVDR and is intended for use by healthcare professionals within a molecular laboratory environment. Yourgene® QSTR Base is a highly multiplexed, single tube assay containing 22 markers for rapid diagnosis of the common autosomal and sex chromosome aneuploidies during pregnancy. For those women identified as being at high risk of carrying a fetus with one of these conditions, chorionic villus sampling (10-12 weeks) or amniocentesis (14-18 weeks) is offered and QSTR Base would then be used by the laboratory. Autosomal markers are used to detect the three most common viable autosomal trisomies: trisomy 21 (Down's syndrome), trisomy 18 (Edwards' syndrome) and trisomy 13 (Patau's syndrome). The chosen markers are highly informative with results obtained in >99% of samples. IVDR ensures that the Yourgene® QSTR Base assay, which is manufactured for sale in the EU, is assessed against stringent quality, safety and performance requirements. Manufacturers must provide considerable evidence of scientific validity, as well as data demonstrating analytical and clinical performance of the tests. The Yourgene® QSTR Base assay was assessed by British Standards Institution (BSI), an independent conformity assessment body, and was shown to conform to the new regulations.
お知らせ • Oct 08Novacyt S.A. Closure of IT-IS International LimitedNovacyt S.A. announced the closure of its IT-IS International Limited ("IT-IS") subsidiary, effective immediately. IT-IS, a Stokesley-based manufacturer of rapid-PCR instruments, was acquired by Novacyt in 2020 to support the Group's response to COVID-19, where it facilitated the full delivery of the Group's contracts during the period. The PCR instrumentation market has since become saturated, with IT-IS subsequently experiencing several consecutive loss-making years. IT-IS contributed £0.3m to the Group's total revenue in H1 2024 (H1 2023: £0.6million). The Intellectual Property ("IP") that exists within IT-IS will be retained to allow Novacyt to continue an ongoing IP infringement dispute with Roche Diagnostics GmbH. The dispute, instigated by IT-IS, dates back over five years and is currently progressing through the German courts. The Group will provide further updates on the dispute when appropriate.
お知らせ • Sep 26Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024Novacyt S.A. announces the appointment of Dr. John Brown CBE as Chairman effective from 1 October 2024. Dr. Brown was appointed Non-executive Director of Novacyt in September 2023 following the acquisition of Yourgene Health and will succeedJames Wakefield, who is retiring from the Board having been Chairman since before the company joined AIM in 2017. Dr. Brown has over 38 years industry experience, which includes significant capital markets and board experience in the healthcare and life sciences sector. He is currently Chairman of Laverock Therapeutics Ltd. and Calcivis Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd. and CXR Biosciences Ltd. and Senior Non-Executive Director of Quantum Pharma plc. Dr. Brown was appointed to the Board of Yourgene Health in July 2019 as a Non-executive Director and became Chairman in April 2022.
お知らせ • Sep 12Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024Novacyt S.A. announced that they will report first half, 2024 results on Sep 26, 2024
お知らせ • May 22Novacyt S.A., Annual General Meeting, Jun 26, 2024Novacyt S.A., Annual General Meeting, Jun 26, 2024. Location: velizy villacoublay France
お知らせ • May 21Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024Novacyt S.A. announced that they will report fiscal year 2023 results on May 30, 2024
お知らせ • May 01Novacyt S.A. Notes DHSC Application for Summary Judgment DismissedNovacyt S.A. noted the judgment by Mrs. Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs. Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment. The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.
お知らせ • Apr 12+ 1 more updateNovacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024Novacyt S.A. announced that James McCarthy will step down from the Board, effective from 1 May 2024. Dr. Andrew Health, Non-Executive Director will retire from the Board of Directors effective 1 May 2024.
お知らせ • Sep 13Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023Novacyt S.A. announced that they will report Q2, 2023 results on Sep 28, 2023
お知らせ • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).
お知らせ • May 10Novacyt S.A., Annual General Meeting, Jun 15, 2023Novacyt S.A., Annual General Meeting, Jun 15, 2023, at 14:00 Central European Standard Time.